SCD for Acute Kidney Injury and Hepatorenal Syndrome

"Information posted on clinicaltrials.gov reveals that the current recruitment period for this trial began June 9th, 2022 and was recently updated on the 29th of June."

"The primary metric for assessing the efficacy of this selective cytopheretic device trial is evaluating mortality over a 7 day period. Secondary outcomes include measuring changes in coagulation parameters such as Prothrombin Time (PT), Activated Partial Thromboplastin Time (PTT), and International Normalized Ratio (INR) reported in seconds, determining dialysis independence at days 1-5 post procedure, and surveying any alterations to renal function as defined by serum creatinine levels prior to and following dialysis initiation."

"This clinical trial is open to 10 candidates with acute kidney injury, aged between 18 and 80. Eligible participants must have cirrhosis-associated ascites; not be listed for liver transplantation; exhibit deteriorating renal function most likely caused by Hepatorenal Syndrome Type I with decreased glomerular filtration rate (GFR); no improvements in renal performance or intolerance of octreotide/midodrine treatment; capacity to tolerate regional citrate anticoagulation & continuous renal replacement therapy (CRRT) over 24 hours at least; receiving care in an intensive care unit (ICU); absence of shock, bacterial infection,"

"Affirmative. Clinicaltrials.gov provides evidence that enrollment is underway for this medical investigation, which was first posted on June 9th 2022 and most recently amended on the 29th of June. The trial seeks to involve 10 patients at a single location."

"The eligibility criteria for this study requires that all participants are under 80 years of age and above the legal threshold."